Guardant Health price to book ratio GH

Market value divided by the book value of the company's net assets, since 2018.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 56.9×; Aug 2024
8-year median: 13.0×
8-year range: 6.9× to 59.1×
Peer median: 6.6×

Guardant Health's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Aug 2024, at 56.9×.

On the days it had one over the last 8 years, its median was 13.0×, from 6.9× in May 2022 to 59.1× in Jul 2024.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2024	56.9×	11.5×	59.1×
2023	14.0×	10.0×	54.7×
2022	16.7×	6.9×	33.1×
2021	14.3×	10.5×	17.0×
2020	11.8×	7.2×	12.2×
2019	9.1×	7.0×	32.9×
2018	12.7×	11.5×	15.1×

Against its peers

Companies in Medical - Diagnostics & Research nearest Guardant Health's size, closest first, today.

Company	Price to book ratio
GHGuardant Health	n/m
LHLabcorp	3.1×
DGXQuest Diagnostics	3.6×
MEDPMedpace	43.1×
RVTYRevvity	2.5×
MTDMettler-Toledo International	n/m
ILMNIllumina	14.3×
IDXXIDEXX Laboratories	27.4×
WATWaters	2.9×
IQVIQVIA	7.5×
AAgilent Technologies	6.6×
Peer median	6.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Guardant Health

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.